PATH | VRL
Menu

Find resources

Total results with these characteristics: 89

Disease: Malaria

Page 4 of 5
Preparing for Malaria Vaccines in Africa: A Tool for Malaria Vaccine Decision-Making

This fact sheet describes the development of a tool—known as the Malaria Vaccine Decision-Making Framework—to help African countries plan for decisions on the appropriate role of an eventual malaria vaccine within their health systems. The tool …

Author: PATH

Publication date: 2017

Protecting Aluminum-Adjuvanted Vaccines From Freeze Damage

This fact sheet describes how PATH developed a low-cost and straightforward technology for protecting aluminum-adjuvanted liquid vaccines from the irreversible damage that results from freezing. Many current vaccines of importance to global health …

Author: PATH

Publication date: 2012

Public Health Impact and Cost-Effectiveness of the RTS,S/AS01 Malaria Vaccine: A Systematic Comparison of Predictions From Four Mathematical Models

This article, published in The Lancet, reports the results of a study that aimed to assess the public health impact and cost-effectiveness of routine use of the RTS,S/AS01 vaccine in African settings. The models predict a significant public health …

Author: Penny MA, Verity R, Bever CA, et al.

Publication date: 2015

Q&A on the Malaria Vaccine Implementation Programme (MVIP)

This web page provides answers to frequently asked questions about the RTS,S/AS01 (RTS,S) malaria vaccine and the malaria vaccine implementation program, which will assess the operational feasibility of administering the RTS,S vaccine in a real-life …

Author: World Health Organization

Publication date: 2017

Qualification of Standard Membrane-Feeding Assay with Plasmodium falciparum Malaria and Potential Improvements for Future Assays

Vaccines that interrupt malaria transmission are of increasing interest. A robust functional assay to measure this activity would provide a biologically relevant means of evaluating potential vaccine candidates. This article, published in PLOS ONE, …

Author: Miura K, Deng B, Tullo G, et al.

Publication date: 2013

Quantifying Infectious Waste Produced by HIV/AIDS, Malaria, and Tuberculosis Programs and the Needs for Injection Safety Equipment

This document is intended to start discussions around quantifying the need for safe injection equipment and the amount of infectious sharps waste produced by testing and treatment programs for diseases such as HIV/AIDS, tuberculosis, and malaria. …

Author: PATH

Publication date: 2009

Reimagining Global Health: 30 High-Impact Innovations to Save Lives

This inaugural report of the Innovation Countdown 2030 initiative features 30 high-impact innovations that can accelerate the world’s progress toward the proposed 2030 health targets in the United Nations Sustainable Development Goals. The …

Author: PATH

Publication date: 2015

Researching and Addressing Community Perceptions of Vaccines and Malaria

This fact sheet describes PATH's work to assess community perceptions of vaccines and malaria in four African countries—Burkina Faso, Ghana, Kenya, and Mozambique—from 2009 through 2014. The findings have guided the development of …

Author: PATH

Publication date: 2017

RTS,S Frequently Asked Questions (FAQs)

This fact sheet provides answers to commonly asked questions about the RTS,S malaria vaccine, its safety and efficacy, and the World Health Organization-coordinated Malaria Vaccine Implementation Programme expected to begin vaccinations in 2018.

Author: PATH

Publication date: 2017

The RTS,S Malaria Vaccine Candidate

This fact sheet provides information on the RTS,S malaria vaccine candidate and the potential role of a malaria vaccine as a complementary tool in the fight against malaria. It summarizes the development history of RTS,S, the Phase 3 clinical study …

Author: PATH

Publication date: 2017

The RTS,S/AS01 Malaria Vaccine in Children 5 to 17 Months of Age at First Vaccination

This article, published in Expert Review of Vaccines, reviews the findings around the safety and feasibility of the RTS,S/AS01 vaccine in children at 5 to 17 months of age—an age category for which RTS,S/AS01 pilot implementation was recommended …

Author: Vandoolaeghe P, Schuerman L

Publication date: 2016

Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01B With Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara Vectored Vaccines Expressing ME-TRAP

The need for a highly efficacious vaccine against Plasmodium falciparum remains pressing. This article, published in The Journal of Infectious Diseases, reports the results of a study that assessed the safety, efficacy, and immunogenicity of a …

Author: Rampling T, Ewer KJ, Bowyer G, et al.

Publication date: 2016

Safety and Immunogenicity of Pfs25-EPA/Alhydrogel®, a Transmission Blocking Vaccine Against Plasmodium falciparum: An Open Label Study in Malaria Naïve Adults

This article, published in PLoS ONE, shares the results of a Phase 1 trial exploring the safety, immunogenicity, and transmission-blocking activity of a malaria transmission-blocking vaccine candidate, Pfs25-EPA conjugates formulated with …

Author: Talaat KR, Ellis RD, Hurd J, et al.

Publication date: 2016

Safety and Immunogenicity of RTS,S/AS01 Malaria Vaccine in Infants and Children With WHO Stage 1 or 2 HIV Disease: A Randomised, Double-Blind, Controlled Trial

Malaria remains a major global public health concern, especially in sub-Saharan Africa. This article, published in The Lancet Infectious Diseases, reports the results of a study that aimed to assess the safety and immunogenicity of RTS,S/AS01 …

Author: Otieno L, Oneko M, Otieno W, et al.

Publication date: 2016

Safety and Immunogenicity of RTS,S/AS02D Malaria Vaccine in Infants

This study, published in the New England Journal of Medicine, assessed the feasibility of integrating the RTS,S/AS02D malaria vaccine into a standard expanded program on immunization (EPI) schedule for infants. The study, conducted in …

Author: Abdulla S, Oberholzer R, Juma O, et al.

Publication date: 2008

Safety of the RTS,S/AS02A Malaria Vaccine in Mozambican Children During a Phase IIb Trial

This study, published in the journal Vaccine, evaluated the safety of the RTS,S/AS02A malaria vaccine in a proof of concept Phase IIb trial in Mozambican children aged one to four years. Overall, the study results indicate that the …

Author: Sacarlal J, Aponte JJ, Aide P, et al.

Publication date: 2008

Status of Vaccine Research and Development of Vaccines for Malaria

This article, published in Vaccine, provides an overview of malaria disease and outlines current efforts in vaccine development. It includes general approaches to vaccine development for low- and middle-income markets, the status of malaria vaccine …

Author: Birkett AJ

Publication date: 2016

Staying the Course? Malaria Research and Development in a Time of Economic Uncertainty

This technical report from the Roll Back Malaria Partnership and partners shines a spotlight on recent trends in investments in malaria research and development (R&D). The report follows up on a 2005 study by the Malaria R&D Alliance to …

Author: PATH

Publication date: 2011

Summary of Vaccine Stability Data

These documents provide stability data as of November 2012 on commonly used, licensed vaccines and stability data as of May 2012 from available data on novel, investigational vaccine formulations. Data are sorted by vaccine in a table format in both …

Author: PATH, Working in Tandem Ltd.

Publication date: 2012

Systems Analysis of Protective Immune Responses to RTS,S Malaria Vaccination in Humans

RTS,S/AS01 is the most advanced malaria vaccine candidate in development, however very little is understood about how it induces immunity. This article, published in Proceedings of the National Academy of Sciences, uses a systems biology approach to …

Author: Kazmin D, Nakaya HI, Lee EK, et al.

Publication date: 2017

Page 4 of 5